- Home
- RFM vs KZIA Comparison
RFM vs KZIA Comparison
Compare RFM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFM | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 100.8M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | RFM | KZIA |
|---|---|---|
| Price | $14.56 | $10.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 11.5K | ★ 198.1K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.68 | $4.86 |
| 52 Week High | $14.90 | $17.40 |
Technical Indicators
Market Signals| Indicator | RFM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 41.11 |
| Support Level | $14.22 | $5.71 |
| Resistance Level | $14.54 | $14.57 |
| Average True Range (ATR) | 0.14 | 1.07 |
| MACD | 0.00 | -0.36 |
| Stochastic Oscillator | 65.35 | 11.06 |
Price Performance
Historical ComparisonAbout RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.